A pilot study suggests that the mTOR inhibitor sirolimus could also be a generally safe and an alternative option in the management of lupus nephritis in patients who are intolerant to standard therapy or in cases of a history of malignancy (31). The gene discussed is MTOR; the disease is lupus nephritis.